Monitoring Afatinib Treatment in HER2-Positive Gastric Cancer with (18)F-FDG and (89)Zr-Trastuzumab PET

We evaluated the ability of the PET imaging agent (89)Zr-trastuzumab to delineate HER2-positive gastric cancer and to monitor the pharmacodynamic effects of the epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitor afatinib. METHODS: Using...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Nucl Med
Prif Awduron: Janjigian, Yelena Y., Viola-Villegas, Nerissa, Holland, Jason P., Divilov, Vadim, Carlin, Sean D., Gomes-DaGama, Erica M., Chiosis, Gabriela, Carbonetti, Gregory, de Stanchina, Elisa, Lewis, Jason S.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2013
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4967936/
https://ncbi.nlm.nih.gov/pubmed/23578997
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.112.110239
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg